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Review PADI4 and tumourigenesis
Xiaotian Chang* and Kehua Fang
Abstract
PADI4 post-translationally converts peptidylarginine to citrulline, a process called citrullination. Studies have 
demonstrated the high expression of PADI4 in various malignant tumour tissues. PADI4 is also expressed at high levels 
in the blood of patients with some malignant tumours. Thus far, citrullination of histone, cytokeratin, antithrombin and 
fibronectin have been confirmed to be involved in abnormal apoptosis, high coagulation, and disordered cell 
proliferation and differentiation, all of which are main features of malignant tumours. PADI4 is expressed in CD34+ stem 
cells in normal tissues, and many more CD34+ cells expressing PADI4 are present in tumour tissues. These findings 
suggest that PADI4 may play an important role in tumourigenesis.
Introduction
Peptidylarginine deiminase (PAD) can catalyse peptidyl
arginine to citrulline in the presence of Ca2+ ions, a reac-
tion known as citrullination, which leads to the post-
translational modification of proteins. Genes encoding
PAD family members, including PADI1, PADI2, PADI3,
PADI4, and PADI6, cluster at human chromosome posi-
tion 1p36.13. The high sequence identity of the C-termi-
nal domains of all PADs suggests that their structures are
similar [1]. The expression of all of these isoforms has
been detected in numerous tissues. PADI1 is found in the
skin epidermis [2], PADI2 is present in various tissues
including brain and muscle [3,4], PADI3 is localised in
hair follicles [5], PADI4 is mainly expressed in granulo-
cytes and monocytes [6], and PADI6 is specially
expressed in embryonic stem cells and oocytes [7,8].
Studies have reported that PADs are involved in cell dif-
ferentiation, apoptosis, nerve growth, embryonic devel-
opment, and gene regulation [9]. Biochemical and
immunohistochemical assays have suggested the involve-
ment of PADI1 in the terminal differentiation of the epi-
dermis [10], PADI2 in the myelination and citrullination
of central nerve axons [11,12], and PADI3 in the keratini-
sation of hair follicles [3,13]. Arginine residues frequently
function as ligand recognition sites in proteins. Some
enzymes that interact with negatively charged substrates
or cofactors have an arginine residue as an anion recogni-
tion site [14]. Therefore, it seems possible that PADs and
citrullination participate in the regulation of these
enzymes. In addition, PAD citrullination was suggested
t o  m o d i fy  t h e  a c t i o n  o f  t ry p s i n - l i k e  e n z y m e s  [ 1 5 ]  a n d
trypsin inhibitors [14], to interfere with intermediate fila-
ment assembly [16], and to play a role in rapid cellular
turnover in tissues with secretory activity [17]. However,
the physiological significance of each of the PADs has not
been understood in detail.
PADI4 was initially cloned from the HL-60 cell line
(human promyelocytic leukaemia cells) [6]. The protein is
663-amino acids long with a molecular weight of 74,095
Da. The PADI4 polypeptide chain has two spherical sub-
units at the N terminus, one α helix\β fold structure at the
C terminus, and five Ca2+ ion-binding sites. The binding
of Ca2+ ions to PADI4 induces conformational changes in
the peptide chain that result in the formation of active
sites, such that the enzyme enters its active state for the
catalysis of arginine residues into citrulline residues [1].
PADI4 is predominantly expressed in blood lymphocytes
and has been suggested to play a role in inflammation and
the immune response [18-21]. Because PADI4 was also
detected in granulocytes and macrophages induced by
HL60 cells, the enzyme is believed to be involved in the
differentiation and apoptosis of these cells [6]. However,
little is known about the precise function and target sub-
strates of PADI4 under physiological conditions.
PADs and citrullinated proteins are involved in the
pathogenic processes of many human diseases, because
citrullination tends to alter the conformation and activity
of target proteins, leading to changes in physiological and
biochemical activity. Rheumatoid arthritis (RA), an auto-
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immune disease, is characterised by the presence of many
types of autoantibodies against citrullinated proteins in
the blood of patients, indicating that citrullination plays
an essential role in the autoimmune reaction and the
destruction of joint tissues [22,23]. By whole genome SNP
scanning, Suzuki et al. demonstrated a strong association
of PADI4 with RA [24]. Chang et al. detected an elevated
expression of PADI4 in the synovial membrane and syn-
ovial fluid of RA patients [19,25]. In addition, Mastron-
ardi et al. detected citrullination of nucleosome histone
H3 in the cerebral white matter of multiple sclerosis
patients and demonstrated that tumour necrosis factor
(TNF)-α induced PADI4 translocation to the nucleus
[26]. The citrullination of proteins appears to be abnor-
mally increased in Alzheimer's disease, glaucoma, and
neurodegeneration [27-29].
Cancer is one of the leading causes of death in humans.
In recent years, our studies and others' found that PADI4
is highly expressed in a variety of malignant tumours and
that it participates in the process of tumourigenesis. This
review highlights PADI4 expression in tumour tissues as
well as the potential role of PADI4 in the pathogenesis of
cancer.
Expression of PADI4 in various malignant tumours
Tumour tissues and synovial tissues from patients with
RA have a lot of common characteristics. Both tissues
show abnormal cell proliferation, fibrin deposition, coag-
ulation activity, and angiogenesis [30]. Because PADI4 is
one of the genes associated with RA, we speculated that
PADI4 might also play a role in the tumourigenic process.
Using immunohistochemistry, quantitative PCR, and
western blot analysis, we detected significant PADI4
expression in tumour cells of various malignancies,
including breast carcinomas, lung adenocarcinomas,
hepatocellular carcinomas, oesophageal squamous can-
cers, colorectal adenocarcinomas, renal cancers, ovarian
adenocarcinomas, endometrial carcinomas, uterine ade-
nocarcinomas, bladder carcinomas, and chondromas, as
well as in other metastatic carcinomas. However, PADI4
was not expressed in benign leiomyomas of the stomach,
uterine myomas, endometrial hyperplasias, cervical pol-
yps, teratomas, hydatidiform moles, trophoblastic cell
hyperplasias, hyroid adenomas, haemangioma, lymph
hyperplasias, schwannomas, neurofibromas, lipomas, or
cavernous haemangioma of the liver. Additionally, PADI4
expression was not detected in non-tumour tissues,
including cholecystitis, cervicitis, and synovitis of
osteoarthritis, except in certain acutely inflamed tissues
such as in acute gastritis and acute appendicitis. In addi-
tion, western blot analysis detected PADI4 expression in
cultured tumour cell lines including A549 (lung adeno-
carcinoma), SKOV3 (ovarian adenocarcinoma), and
U937 (leukaemia) cells. ELISAs detected increased
PADI4 levels in the blood of patients with various malig-
nant tumours compared to those in patients with chronic
inflammation and benign tumours. PADI4 levels were
also significantly associated with CEA levels, a serum
marker for tumour diagnosis, in the blood of patients
with gastric cancer and prostate cancer [31,32]. Recently,
Lv. et al. reported the significantly increased expression of
PADI4 in hepatocellular carcinomas compared to that in
the surrounding healthy tissues, as determined by west-
ern blot analysis [33]. Stacey et al. conducted a genome-
wide SNP association study and found that common vari-
ants on rs7538876 of 1p36, containing the PAD locus, are
significantly associated with coetaneous basal cell carci-
noma but not with melanoma or pigmentation traits [34].
Many studies have investigated the tissue distribution
of P ADI4 in diseased tissues. In the RA synovial mem-
brane, PADI4 was located in T cells, B cells, granulocytes,
macrophages, and capillary endothelial cells [19]. PADI4
was also detected in eosinophils and neutrophils of
peripheral blood cells [18,19]. In our study, PADI4 was
demonstrated in CD34+ cells of the bone marrow and
normal tissues by double immunolabelling. Although
tumour cells that express PADI4 lacked CD34 signals, the
enzyme is located in CD34+ mesenchymal cells in the
stromal region of the tumour tissues [31]. These observa-
tions and studies by others suggest that PADI4 expression
may be limited to haematopoietogenic lineage cells that
originally develop from haematopoietic cells (HPCs) in
the bone marrow. HPCs marked with CD34 comprise a
well-characterised population of multi-potent progenitor
cells that are able to self-renew and give rise to terminally
differentiated haematopoietic cells, or something more
specific. These stem cells can also differentiate and inte-
grate into various tissues such as skeletal muscle, cardiac
monocytes, vascular endothelium, liver, and brain
[35,36]. Because there are more CD34+ cells expressing
PADI4 in tumour tissues than in normal tissues [31], it is
postulated that the development of PADI4-expressing
tumour cells may be associated with the abnormal prolif-
eration of CD34+ stem cells or their progeny. In fact,
many studies have found a strong association between
CD34 cells and tumourigenesis in the lung, pancreas,
liver, and stomach adenocarcinomas [37-42]. Strobel et al.
reported that human bone marrow cells have the ability
to stimulate the growth, in a dose-dependent manner, of
many types of tumour cells in vitro [43]. Hellwig et al.
found that basic fibroblast growth factor (bFGF) and vas-
cular endothelial growth factor (VEGF), both of which
are increased with the progression of tumourigenesis,
suppress the expression of CD34 in renal carcinoma.
Such a down-regulation of CD34 adhesion molecules
may allow tumour cells to escape immune surveillance
[44]. Their findings may explain the disappearance ofChang and Fang Cancer Cell International 2010, 10:7
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CD34 expression in PADI4-expressing tumour cells
observed in our study.
Citrullination of proteins
PADI4 exerts post-translational modifications through
the conversion of arginine to citrulline. Therefore, the
identification of PADI4 substrates is helpful for under-
standing the pathogenic mechanisms of the enzyme dur-
ing tumourigenesis.
P53 inhibits malignant transformation through the
transcriptional regulation of its target genes to mediate
the cell cycle and apoptosis [45,46]. Under normal cir-
cumstances, damaged, aging, or diseased cells increase
their expression of p53, activating its downstream target
genes and eventually inducing apoptosis to ensure the
health of the body [47]. Studies have indicated that p53
regulates the transcription of target genes by post-trans-
lational modification of histones via methylation, acetyla-
tion, phosphorylation, ubiquitination, and citrullination
[48,49]. Using chromosome immunoprecipitation, Yao et
al. and Li et al. investigated the promoters of p53 target
genes and found that over-expression of PADI4 may pre-
vent arginine methyltransferase from methylating histone
H3 by converting arginine residues into citrulline. As a
result, the expression of p53 target genes is reduced,
resulting in the disruption of cellular apoptosis and the
normal cell cycle [50,51]. Hagiwara et al. and Cuthbert et
al. also confirmed that the citrullination of histones by
PADI4 antagonises arginine methylation [52,53]. Using
cultured human leukaemia HL-60 cells and human acute
T leukaemia Jurkat cells, Liu et al. found that the over-
expression of PADI4 could induce the up-regulation of
p53, p21, and Bax expression, resulting in cell cycle arrest
and mitochondria-mediated apoptosis [54]. However, Lv
et al. recently detected decreased p53 levels in tumour
tissues from patients with hepatocellular carcinomas
compared to the surrounding healthy tissues. They also
found that the expression of p53 was obviously decreased
in HeLa cells transfected with a PcDNA3.0-Flag-PADI4
plasmid, suggesting that the enzyme induces tumouri-
genesis by down-regulating p53 expression [33].
Cytokeratin (CK), the intermediate filament protein,
constitutes the cytoskeleton and plays an important role
in cellular stress, signal transduction, and apoptosis. CK,
as a tumour-specific marker, displays high expression in
gastric cancer, pancreatic cancer, breast cancer, urinary
tract transitional cell carcinoma, and other tumour epi-
thelial cells [55,56]. Omary et al. have found that the gly-
cosylation, phosphorylation, and other post-translational
modifications of CK change its solubility and other physi-
cal and chemical properties that lead to cellular apoptosis
in a variety of physiological processes [57]. By immuno-
histochemistry and western blotting, we found that
PADI4 and CK have similar distributions in the colon,
oesophagus, bladder, lung, rectum, stomach and breast
cancer, thyroid tumour, oesophageal squamous cell carci-
noma, hepatocellular carcinoma, and other non-adeno-
carcinomas. Co-immunoprecipitation indicated the
citrullination of CK8, 18, and 19 in tumour tissues. Fol-
lowing the citrullination of PADI4, CK is not digested by
caspase, thereby disrupting the process of apoptosis [31].
An imbalance of apoptosis is one of the characteristics of
malignant tumours.
Antithrombin (AT) is a member of the serine protease
inhibitor (serpin) superfamily, and it inhibits plasma
thrombin activity to maintain the dynamic equilibrium of
the coagulation and anti-coagulation system. Structural
changes in AT may lead to abnormal blood clotting. It is
reported that approximately 90% of cancer patients are at
risk of thrombosis [58]. We incubated recombinant
PADI4 with human AT. Western blots and ELISA showed
that the citrullination of AT decreased its ability to inhibit
thrombin [59]. Recently, Ordóñez A. et al. confirmed by
proteomic analysis that the citrullination of antithrombin
abolished its activity. They also found that this abolition
of activity was accelerated by heparin, which facilitated
the citrullination of Arg393 (P1 residue). Their proteomic
analyses revealed nine additional citrullines that caused a
significant decrease in its electrostatic potential [60].
U s i n g  s a n d w i c h  E L I S A ,  w e  d e t e c t e d  h i g h e r  l e v e l s  o f
PADI4 and citrullinated AT levels in the plasma of
patients with malignant tumours, including those with
breast carcinomas, hepatocellular carcinomas, lung carci-
nomas, oesophageal carcinomas, gastric cancer, colon
cancer, rectal cancer, pancreatic cancer, ovarian carcino-
mas, bladder carcinomas, uterine myomas, thyroid carci-
nomas, and prostate carcinomas. The levels of
citrullinated antithrombin were significantly associated
with PADI4 levels in blood of patients with hepatocellular
carcinomas, lung cancer, ovarian cancer, endometrial car-
cinomas, and thyroid adenomas. In addition, the levels of
citrullinated AT were clearly associated with the CEA
levels in the blood of patients with breast carcinomas,
bladder cancer, renal cell carcinomas, and pancreatic can-
cer; with CA199 levels in those with gastric cancer; with
CA125 levels in those with ovarian cancer; and with PSA
in those with prostate cancer [32]. CEA, CA199, CA125,
and PSA are tumour makers and are currently used for
tumour diagnosis. These results suggest that PADI4 may
be responsible for the high coagulation activity induced
by the citrullination of AT in cancer patients. Studies
have shown that an increase in thrombin activity can pro-
mote fibrin deposition, angiogenesis, and tumour cell
invasion and metastasis, ultimately leading to the malig-
nant proliferation of tumour cells [61].
Fibronectin (Fn) is a glycoprotein that is widely present
in the extracellular matrix, plasma, and other body fluids.
Structurally, it contains multiple functional domains thatChang and Fang Cancer Cell International 2010, 10:7
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interact with the extracellular matrix, integrin receptors,
and growth factors, which play important roles in cell
adhesion, migration, differentiation, and proliferation. A
number of studies have demonstrated an important role
of Fn in tumourigenesis [62,63]. Our in vitro study
showed that rabbit PAD may catalyse citrullination of
both the cellular and serum Fn. Following citrullination,
the affinity of Fn for VEGF increases, but its binding
activity to integrin β 1 decreases, and Fn no longer stimu-
lates the apoptosis of monocytes induced from cultured
HL-60 cells [64]. Therefore, it is suggested that Fn may
also be citrullinated by PADI4 in tumours, thus leading to
tumour cell invasion, proliferation, and malignancies.
Regulatory mechanism of PADI4
To date, little is known about the mechanisms that regu-
late PADI4. Dong et al. found that oestrogen regulates the
expression of PADI4 through both the classical and non-
classical pathways [65]. In the classical way, oestrogen
binds to the oestrogen receptor to form a complex and
then regulates PADI4 expression via the oestrogen
response element on the promoter. In the non-classical
pathway, the oestrogen-oestrogen receptor complex acts
on the transcription factors AP-1, NF-Y, and SP-1, which
bind to the PADI4 promoter to specifically regulate
PADI4 expression. On the other hand, Cuthbert et al.
found that PADI4 could suppress the expression of
oestrogen-regulated genes by antagonizing the methyla-
tion of histone H3 on the pS2-promotors of these genes
by citrullination [53]. It is possible that oestrogen regu-
lates oestrogen-sensitive genes by a negative feedback
effect via the citrullination of PADI4. Recently, Tanikawa
et al. reported that p53 transactivated PADI4 through a
p53-binding site located in the first intron. Furthermore,
they found that the knockdown of PADI4 attenuated p53-
mediated growth-inhibitory activity, demonstrating the
significance of PADI4-mediated protein citrullination in
the p53 signalling pathway [66]. This result seems contro-
versial in light of the findings that PADI4 disrupts the
apoptotic process via the citrullination of histone H3 on
the promoter of p53-target genes [50,51], but it is consis-
tent with the result that over -expression of P ADI4 can
induce apoptosis [54].
We review the following regulatory mechanism of
PADI4 by summarizing our studies and those of others
(Figure 1).
PADI4, a potential biomarker
T o  d a t e ,  a  n u m b e r  o f  b i o m a r k e r s  h a v e  b e e n  u s e d  f o r
tumour diagnosis. However, the specificity and sensitivity
are inappropriate for large-scale surveys of tumour prog-
nosis, because these tumour markers can only be
expressed in one or several kinds of tumours. PADI4 is
highly expressed in a variety of malignant tumours but is
either not expressed or is expressed at very low levels in
normal tissues and benign tissues. The enzyme can be
considered as an immunohistochemical barometer to dis-
tinguish tumour cells from non-tumour cells and to
define the tissue structure of tumours. Because patients
with various malignant tumours display an increased
expression of PADI4 in their blood, and because the level
of expression declines after tumour excision surgery [32],
the enzyme can be used as a serum maker of tumours to
compensate for some of the deficiencies in the current
methods employed for tumour diagnosis. In addition, the
specific nature of PADI4 expression in tumour cells
makes PADI4 a potential target for cancer therapy.
Hence, PADI4 could have important clinical applications;
however, further research is necessary to develop this
marker into a useful clinical diagnostic tool.
Conclusion
In summary, PADI4 demonstrates significant expression
in various malignant tissues but maintains a low level of
expression in normal and benign tissues. Studies have
indicated that PADI4 may be involved in tumourigenesis
via the citrullination of histone, cytokeratin, antithrom-
bin, and fibronectin; although some studies suggest that
the enzyme can induce apoptosis.
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Figure 1 regulatory mechanism of PADI4 - study summary.
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